This inventor holds 15 USPTO granted patents, plus 1 CIPO patent, primarily in Glycopeptide Antibiotics. Top assignee: Eli Lilly and Company. Active years: 1978-2000.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1978-2000
Areas of Expertise:
Title: Innovative Contributions of Ramakrishnan Nagarajan
Introduction
Ramakrishnan Nagarajan, based in Indianapolis, IN, has made significant contributions to the field of biotechnology, holding a remarkable portfolio of 15 patents. His innovative work primarily focuses on glycopeptide antibiotics, which play a crucial role in combating bacterial infections, particularly those caused by Gram-positive microorganisms.
Latest Patents
Among his latest patents, Nagarajan has developed compounds related to A-82846-type glycopeptide antibiotics. These compounds are produced by treating antibiotics from the A82846 components A, B, and C with trifluoroacetic acid. This treatment effectively removes specific groups attached to the disaccharide, resulting in compounds that demonstrate strong antibacterial activity. Additionally, he has created new N-alkyl and N-acyl derivatives of A82846A, A82846B, A82846C, and PA-42867-A. These glycopeptide derivatives are particularly beneficial for treating bacterial infections due to their efficacy against Gram-positive microorganisms.
Career Highlights
Ramakrishnan is currently affiliated with Eli Lilly and Company, a leading global pharmaceutical company known for its research and innovative products. His work has consistently focused on advancing antibiotic therapies, showcasing his dedication to improving health outcomes through scientific research.
Collaborations
Throughout his career, Nagarajan has collaborated with notable colleagues, including Amelia A. Schabel and Marvin Gorman. These collaborations have fostered a productive environment for innovation and have contributed to the successful development of various patented compounds.
Conclusion
Ramakrishnan Nagarajan's work exemplifies the impact of dedicated research and innovation in the field of pharmaceuticals. With 15 patents to his name, his contributions to glycopeptide antibiotics not only enhance our understanding of bacterial treatments but also signify a commitment to fighting resistant strains of bacteria, preserving health and well-being in society.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile